Insider Selling: Hologic, Inc. (HOLX) SVP Sells 7,000 Shares of Stock
Hologic, Inc. (NASDAQ:HOLX) SVP Allison P. Bebo sold 7,000 shares of the firm’s stock in a transaction on Friday, March 16th. The stock was sold at an average price of $38.75, for a total value of $271,250.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Hologic, Inc. (NASDAQ HOLX) opened at $38.15 on Friday. Hologic, Inc. has a twelve month low of $35.33 and a twelve month high of $46.80. The company has a current ratio of 1.25, a quick ratio of 0.98 and a debt-to-equity ratio of 0.87. The firm has a market capitalization of $10,560.65, a price-to-earnings ratio of 18.63, a PEG ratio of 1.72 and a beta of 0.84.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.05. Hologic had a return on equity of 20.07% and a net margin of 34.53%. The firm had revenue of $791.10 million during the quarter, compared to the consensus estimate of $785.80 million. During the same period last year, the company earned $0.52 earnings per share. The company’s revenue was up 7.7% on a year-over-year basis. sell-side analysts anticipate that Hologic, Inc. will post 2.25 EPS for the current fiscal year.
HOLX has been the subject of a number of research reports. Bank of America upgraded Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price objective for the company in a report on Thursday, January 4th. Goldman Sachs upgraded Hologic from a “buy” rating to a “conviction-buy” rating and increased their price objective for the stock from $45.00 to $50.00 in a report on Friday, December 8th. Zacks Investment Research downgraded Hologic from a “buy” rating to a “hold” rating in a report on Tuesday, March 6th. Deutsche Bank downgraded Hologic from a “buy” rating to a “hold” rating and set a $49.00 price objective for the company. in a report on Friday, January 19th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $48.00 price objective (up previously from $46.00) on shares of Hologic in a report on Tuesday, December 5th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Hologic currently has an average rating of “Buy” and an average price target of $48.00.
TRADEMARK VIOLATION NOTICE: “Insider Selling: Hologic, Inc. (HOLX) SVP Sells 7,000 Shares of Stock” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/insider-selling-hologic-inc-holx-svp-sells-7000-shares-of-stock/1960575.html.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.